Visterra
Biologics research company focused on discovery and development of antibody-based therapeutics for immune-mediated and hard-to-treat diseases. The organization integrates single-cell multi-omics, computational methods including machine learning, protein engineering, and experimental approaches to design epitope-targeted biologics and advance programs through preclinical IND-enabling work and clinical development. Located in the greater Cambridge/Boston area and operating in partnership with external research and commercial organizations.
Industries
Nr. of Employees
medium (51-250)
Patents
Products
Antibody therapeutic programs targeting APRIL for IgA nephropathy
Antibody programs targeting APRIL in development for IgA nephropathy; one APRIL-targeting antibody program is in clinical development and has associated regulatory and commercialization activities with development partners.
Sibeprenlimab
A selective IgG2 antibody that binds to and inhibits the biological activity of APRIL, evaluated for the treatment of patients with IgA nephropathy.
Sibeprenlimab (VIS649)
A therapeutic candidate being evaluated for the treatment of IgA nephropathy and Sjögren Disease.
VOYXACT
A humanized monoclonal antibody that binds to and blocks APRIL, approved for the reduction of proteinuria in adults with Primary Immunoglobulin A Nephropathy (IgAN) at risk for disease progression.
VIS171
A therapeutic candidate being evaluated in a Phase 1 clinical trial for participants with autoimmune disease(s).
ViSTAR
Proprietary Fc-modification technology introduced to enhance the activity of lead candidates, modify half-life, and modulate effector function.
Antibody therapeutic programs targeting APRIL for IgA nephropathy
Antibody programs targeting APRIL in development for IgA nephropathy; one APRIL-targeting antibody program is in clinical development and has associated regulatory and commercialization activities with development partners.
Sibeprenlimab
A selective IgG2 antibody that binds to and inhibits the biological activity of APRIL, evaluated for the treatment of patients with IgA nephropathy.
Sibeprenlimab (VIS649)
A therapeutic candidate being evaluated for the treatment of IgA nephropathy and Sjögren Disease.
VOYXACT
A humanized monoclonal antibody that binds to and blocks APRIL, approved for the reduction of proteinuria in adults with Primary Immunoglobulin A Nephropathy (IgAN) at risk for disease progression.
VIS171
A therapeutic candidate being evaluated in a Phase 1 clinical trial for participants with autoimmune disease(s).
ViSTAR
Proprietary Fc-modification technology introduced to enhance the activity of lead candidates, modify half-life, and modulate effector function.
Services
Epitope-focused discovery, computational design, library screening and protein engineering to generate lead biologic candidates.
Nonclinical pharmacology, bioanalytical assay support and toxicology-focused activities to enable regulatory submissions and transition to first-in-human studies.
Process development engineering, scale-up, and technology transfer activities to support manufacturing of biologic drug substance.
Support and management of Phase 1–3 clinical trials for biologic candidates, including program coordination with external development partners.
Epitope-focused discovery, computational design, library screening and protein engineering to generate lead biologic candidates.
Nonclinical pharmacology, bioanalytical assay support and toxicology-focused activities to enable regulatory submissions and transition to first-in-human studies.
Process development engineering, scale-up, and technology transfer activities to support manufacturing of biologic drug substance.
Support and management of Phase 1–3 clinical trials for biologic candidates, including program coordination with external development partners.
Expertise Areas
- Antibody discovery and engineering
- Computational biology and AI-driven target discovery
- Protein design and structural modeling
- Single-cell multi-omic analysis
Key Technologies
- Single-cell multi-omics
- Machine learning / AI for target discovery
- De novo protein design
- Structural modeling
News & Updates
Presentation of a prespecified interim analysis from a Phase 3 study evaluating the effect of an APRIL-targeting antibody on eGFR in adults with IgA nephropathy.
Conference presentation describing preclinical development of an IL-2 mutein that selectively upregulates regulatory T cells to treat autoimmune diseases.
Peer-reviewed Phase 2 clinical trial publication reporting outcomes of an APRIL-targeting antibody in patients with IgA nephropathy.
Review describing applications of multi-omic single-cell sequencing for therapeutic development in kidney disease.
Publication comparing icIEF-UV/MS methods to traditional fractionation workflows for therapeutic antibody characterization.
Presentation of a prespecified interim analysis from a Phase 3 study evaluating the effect of an APRIL-targeting antibody on eGFR in adults with IgA nephropathy.
Conference presentation describing preclinical development of an IL-2 mutein that selectively upregulates regulatory T cells to treat autoimmune diseases.
Peer-reviewed Phase 2 clinical trial publication reporting outcomes of an APRIL-targeting antibody in patients with IgA nephropathy.
Review describing applications of multi-omic single-cell sequencing for therapeutic development in kidney disease.
Publication comparing icIEF-UV/MS methods to traditional fractionation workflows for therapeutic antibody characterization.